For research use only. Not for therapeutic Use.
ZINC00640089 is a specific Lipocalin-2 (LCN2) inhibitor. ZINC00640089 inhibits cell proliferation, cell viability and reduces AKT phosphorylation levels in SUM149 cells. ZINC00640089 has good potential for research in inflammatory breast cancer (IBC)[1].
ZINC00640089 (0.01-100 µM; 72 h) reduces cell proliferation and cell viability in SUM149 cells[1].
ZINC00640089 (1, 10 µM; 15 min, 1 h) reduces the p-Akt levels in SUM149 cells[1].
| Catalog Number | I042521 |
| CAS Number | 667880-11-7 |
| Synonyms | 2-(2-oxobenzo[cd]indol-1-yl)-N-[2-(trifluoromethyl)phenyl]acetamide |
| Molecular Formula | C20H13F3N2O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H13F3N2O2/c21-20(22,23)14-8-1-2-9-15(14)24-17(26)11-25-16-10-4-6-12-5-3-7-13(18(12)16)19(25)27/h1-10H,11H2,(H,24,26) |
| InChIKey | BJLGMVSRCCPPDE-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C(=C1)C(F)(F)F)NC(=O)CN2C3=CC=CC4=C3C(=CC=C4)C2=O |
| Reference | [1]. Santiago-Sánchez GS, et al. Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors. Int J Mol Sci. 2021 Aug 10;22(16):8581. |
